Inventor · disambiguated record
Neil Stahl
Also filed as: STAHL NEIL · STAHL NEIL E
53 granted patents·20 pending applications·1,255 citations·filing 1992–2025
99Inventor score
Files withREGENERON PHARMA67
Top patents by PatentIndex Score
73 records- 0199US7435553B2Isolating cells expressing secreted proteinsREGENERON PHARMA·Filed 2006·Granted Oct 14, 2008·104 cites·15 claims
- 0298US9540449B2Anti-PCSK9 antibodies with pH-dependent binding characteristicsREGENERON PHARMA·Filed 2013·Granted Jan 10, 2017·57 cites·13 claims
- 0398US6927044B2IL-1 receptor based cytokine trapsREGENERON PHARMA·Filed 2002·Granted Aug 9, 2005·133 cites·30 claims
- 0497US10975139B1Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragmentsREGENERON PHARMA·Filed 2020·Granted Apr 13, 2021·15 cites·20 claims
- 0597US10954289B1Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragmentsREGENERON PHARMA·Filed 2020·Granted Mar 23, 2021·28 cites·28 claims
- 0697US10787501B1Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragmentsREGENERON PHARMA·Filed 2020·Granted Sep 29, 2020·224 cites·20 claims
- 0797US10676530B2Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an antibody to IL-4 receptorREGENERON PHARMA·Filed 2017·Granted Jun 9, 2020·14 cites·24 claims
- 0897US10669341B2Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an antibody to IL-4 receptorREGENERON PHARMA·Filed 2017·Granted Jun 2, 2020·13 cites·20 claims
- 0997US10392439B2Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an IL-4R inhibitorREGENERON PHARMA·Filed 2014·Granted Aug 27, 2019·22 cites·11 claims
- 1097US6919183B2Isolating cells expressing secreted proteinsREGENERON PHARMA·Filed 2002·Granted Jul 19, 2005·88 cites·47 claims
- 1196US11530255B2Human antibodies to Ebola virus glycoproteinREGENERON PHARMA·Filed 2020·Granted Dec 20, 2022·3 cites·18 claims
- 1296US9771414B2Human antibodies to ebola virus glycoproteinREGENERON PHARMA·Filed 2016·Granted Sep 26, 2017·18 cites·32 claims
- 1394US10501526B2Human antibodies to Ebola virus glycoproteinREGENERON PHARMA·Filed 2018·Granted Dec 10, 2019·11 cites·13 claims
- 1494US9718872B2Human antibodies to middle east respiratory syndrome—coronavirus spike proteinREGENERON PHARMA·Filed 2015·Granted Aug 1, 2017·18 cites·25 claims
- 1594US7531172B2Methods of treating diseases with a VEGF antagonistREGENERON PHARMA·Filed 2006·Granted May 12, 2009·30 cites·10 claims
- 1694US6811780B2Methods of using cytokine antagonists to treat HIV infection and AIDSREGENERON PHARMA·Filed 2003·Granted Nov 2, 2004·49 cites·13 claims
- 1794US6472179B2Receptor based antagonists and methods of making and usingREGENERON PHARMA·Filed 1999·Granted Oct 29, 2002·108 cites·25 claims
- 1893US11732030B2Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragmentsREGENERON PHARMA·Filed 2021·Granted Aug 22, 2023·2 cites·51 claims
- 1993US10081670B2Human antibodies to Ebola virus glycoproteinREGENERON PHARMA·Filed 2017·Granted Sep 25, 2018·10 cites·13 claims
- 2093US7927583B2Receptor based antagonists and methods of making and usingREGENERON PHARMA·Filed 2008·Granted Apr 19, 2011·11 cites·8 claims
- 2192US11485788B2Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an IL-4R inhibitorREGENERON PHARMA·Filed 2020·Granted Nov 1, 2022·2 cites·12 claims
- 2292US7351411B2Methods of treating anemia by inhibition of vascular endothelial growth factor (VEGF)REGENERON PHARMA·Filed 2006·Granted Apr 1, 2008·23 cites·12 claims
- 2392US7083950B2High affinity fusion proteins and therapeutic and diagnostic methods for useREGENERON PHARMA·Filed 2003·Granted Aug 1, 2006·26 cites·14 claims
- 2491US10829544B2Human antibodies to Ebola virus glycoproteinREGENERON PHARMA·Filed 2019·Granted Nov 10, 2020·2 cites·20 claims
- 2591US5844099ACytokine antagonistsREGENERON PHARMA·Filed 1995·Granted Dec 1, 1998·87 cites·17 claims
- 2686US12251440B2Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragmentsREGENERON PHARMA·Filed 2023·Granted Mar 18, 2025·0 cites·16 claims
- 2786US10598669B2Isolating cells expressing secreted proteinsREGENERON PHARMA·Filed 2019·Granted Mar 24, 2020·1 cites·20 claims
- 2886US9389236B2Isolating cells expressing secreted proteinsREGENERON PHARMA·Filed 2013·Granted Jul 12, 2016·3 cites·34 claims
- 2986US5470952ACNTF and IL-6 antagonistsREGENERON PHARMA·Filed 1993·Granted Nov 28, 1995·47 cites·2 claims
- 3085US10406222B2Human antibodies to Middle East Respiratory Syndrome—coronavirus spike proteinREGENERON PHARMA·Filed 2017·Granted Sep 10, 2019·4 cites·11 claims
- 3185US7361350B2Use of an IL-1 antagonist for treating arthritisREGENERON PHARMA·Filed 2005·Granted Apr 22, 2008·6 cites·9 claims
- 3283US12152067B2Human antibodies to ebola virus glycoproteinREGENERON PHARMA·Filed 2022·Granted Nov 26, 2024·0 cites·57 claims
- 3381US2023159647A1Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r inhibitorREGENERON PHARMA·Filed 2022·Application pending·0 cites
- 3480US7417134B2IL-1 receptor based cytokine traps and method of usingREGENERON PHARMA·Filed 2005·Granted Aug 26, 2008·2 cites·13 claims
- 3579US10261093B2Isolating cells expressing secreted proteinsREGENERON PHARMA·Filed 2015·Granted Apr 16, 2019·1 cites·13 claims
- 3675US6075007AModified noggin polypeptide and compositionsREGENERON PHARMA·Filed 1997·Granted Jun 13, 2000·20 cites·6 claims
- 3773US2020326349A1Isolating Cells Expressing Secreted ProteinsREGENERON PHARMA·Filed 2020·Application pending·0 cites
- 3873US2024124554A1Vegf traps and mini-traps and methods for treating ocular disorders and cancerREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 3972US7285532B2Therapeutic method for treating bone formation diseasesREGENERON PHARMA·Filed 2003·Granted Oct 23, 2007·2 cites·4 claims
- 4070US6767894B1Use of ciliary neurotrophic factorREGENERON PHARMA·Filed 2000·Granted Jul 27, 2004·5 cites·7 claims
- 4170US2009137416A1Isolating Cells Expressing Secreted ProteinsREGENERON PHARMA·Filed 2008·Application pending·0 cites
- 4269US12325752B2Immunoglobulin proteins that bind to NPR1 agonistsREGENERON PHARMA·Filed 2021·Granted Jun 10, 2025·0 cites·44 claims
- 4369US10072076B2Human antibodies to NAv1.7REGENERON PHARMA·Filed 2014·Granted Sep 11, 2018·1 cites·10 claims
- 4469US2020299414A1Multivalent Antigen-Binding ProteinsREGENERON PHARMA·Filed 2020·Application pending·0 cites
- 4568US6610510B1Morphogenic proteinsREGENERON PHARMA·Filed 1998·Granted Aug 26, 2003·20 cites·8 claims
- 4667US2015160215A1Isolating cells expressing secreted proteinsREGENERON PHARMA·Filed 2014·Application pending·0 cites
- 4765US12103960B2VEGF traps and mini-traps and methods for treating ocular disorders and cancerREGENERON PHARMA·Filed 2021·Granted Oct 1, 2024·0 cites·10 claims
- 4865US2025333524A1Immunoglobulin proteins that bind to npr1 agonistsREGENERON PHARMA·Filed 2025·Application pending·0 cites
- 4964US12459991B2Compositions and methods for using bispecific antibodies to bind complement and a target antigenREGENERON PHARMA·Filed 2020·Granted Nov 4, 2025·0 cites·7 claims
- 5064US6846908B2DCR-5 bone affecting ligandREGENERON PHARMA·Filed 2003·Granted Jan 25, 2005·0 cites·6 claims
Showing the top 50 of 73 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Neil Stahl files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →